세계의 가성 장 폐색 치료 시장 보고서(2025년)
Intestinal Pseudo-Obstruction Treatment Global Market Report 2025
상품코드 : 1825424
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

가성 장 폐색 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 5.6%로 308억 달러로 성장합니다. 예측 기간의 성장은 연구개발 및 의약품 개발, 원격의료 및 원격 모니터링, 환자 교육 및 지원, 상환 정책에 기인합니다. 예측 기간의 주요 동향으로는 첨단 소화관 운동 검사, 면역 조절 요법, 영양 중재, 데이터 분석, AI 등이 있습니다.

향후 5년간 5.6%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과로 인해 영국과 이탈리아에서 수입되는 운동 촉진제 및 특수 경장영양 튜브에 대한 접근이 제한되어 운동 장애 관리가 손상되고 재입원율이 높아질 수 있으므로 미국 의료 서비스 프로바이더에게 큰 도전이 될 수 있습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

파킨슨병 유병률 증가는 당분간 장폐색증 치료제 시장 확대의 큰 요인이 될 것으로 예측됩니다. 파킨슨병은 주로 뇌의 흑질 부위에 있는 도파민 생성 뉴런에 영향을 미치는 신경 퇴행성 질환입니다. 파킨슨병 환자에서 IPO의 발병률 증가는 장 신경계에 영향을 미쳐 소화관 운동 장애를 유발하고, 거대결장증이나 급성 가성 결장폐색과 같은 상태를 유발할 수 있습니다. 예를 들어 미국에 본사를 둔 비영리단체인 파킨슨 재단(Parkinson's Foundation)에 따르면 2022년 12월에는 파킨슨병 진단이 눈에 띄게 증가하고 있으며, 연간 약 9만 명의 미국인이 파킨슨병 진단을 받고 있다고 합니다. 또한 2030년까지 전 세계 파킨슨병 환자 수는 120만 명에 달할 것으로 예측되고 있습니다. 그 결과, 파킨슨병 환자 증가는 장폐색 치료제 시장 성장의 원동력이 되고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Intestinal pseudo-obstruction (IPO) treatment addresses a rare gastrointestinal motility disorder exhibiting symptoms akin to a mechanical bowel obstruction, even in the absence of a physical blockage. The goals of treating intestinal pseudo-obstruction involve symptom relief, enhancement of intestinal motility, complication management, and overall improvement in quality of life.

The primary drug classes encompassed in IPO treatment comprise antibiotics, antidepressants, and antidiarrheals. Antibiotics represent a potent category of medications employed for combating bacterial infections in both human and animal patients. Diverse treatment modalities, such as medication, surgery, dietary adjustments, decompression, and others, are administered via various routes, including oral, intravenous, among others. Multiple diagnostic approaches, including physical examinations, biopsies, blood tests, gastric emptying tests, imaging studies, among others, are utilized by a range of end users, including clinics, hospitals, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The intestinal pseudo-obstruction market research report is one of a series of new reports from The Business Research Company that provides intestinal pseudo-obstruction market statistics, including intestinal pseudo-obstruction industry global market size, regional shares, competitors with a intestinal pseudo-obstruction market share, detailed intestinal pseudo-obstruction market segments, market trends and opportunities and any further data you may need to thrive in the intestinal pseudo-obstruction industry. This intestinal pseudo-obstruction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $23.46 billion in 2024 to $24.74 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increased recognition and diagnosis, advancements in medical imaging, advancements in gastrointestinal motility testing, global healthcare access.

The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $30.8 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and ai.

The forecast of 5.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. providers by restricting access to prokinetic agents and specialized enteral feeding tubes imported from the UK and Italy, potentially compromising motility disorder management and increasing hospital readmission rates. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of Parkinson's disease is anticipated to be a significant driver for the expansion of the intestinal pseudo-obstruction (IPO) treatment market in the foreseeable future. Parkinson's disease is a neurodegenerative condition primarily affecting dopamine-producing neurons in the substantia nigra region of the brain. The heightened incidence of IPO in individuals with Parkinson's disease is attributed to its impact on the enteric nervous system, leading to gastrointestinal dysmotility, potentially resulting in conditions like megacolon or acute colonic pseudo-obstruction. For instance, in December 2022, according to the Parkinson's Foundation, a U.S.-based non-profit organization, there has been a notable increase in Parkinson's disease diagnoses, with approximately 90,000 Americans being identified annually, representing a substantial 50% surge from previous estimates. Moreover, it is projected that by 2030, the global population with Parkinson's disease will reach 1.2 million. Consequently, the escalating cases of Parkinson's disease serve as a driving force for the growth of the intestinal pseudo-obstruction treatment market.

The rising number of cancer cases is expected to drive the growth of the intestinal pseudo-obstruction (IPO) treatment market in the coming years. Cancer is a disease where certain cells in the body grow uncontrollably and spread to other areas. Factors such as sedentary lifestyles, poor eating habits, and tobacco use increase the risk of cancer. In the treatment of intestinal pseudo-obstruction (IPO) related to cancer, managing the underlying cancer is a key approach, which can help alleviate or resolve the gastrointestinal symptoms associated with pseudo-obstruction. For example, in October 2022, Macmillan Cancer Support, a UK-based non-profit organization, reported that around 3 million people in the UK are currently living with cancer, with projections suggesting this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the growing incidence of cancer is fueling the expansion of the intestinal pseudo-obstruction (IPO) treatment market.

The increasing demand for personalized medicine is expected to drive the growth of the intestinal pseudo-obstruction (IPO) treatment market in the future. Personalized medicine leverages genetic information to tailor treatments to individual patients. The growing demand for this approach is driven by advancements in genomics, biotechnology, and the rising awareness of genetic testing and precision healthcare. Personalized medicine offers customized treatments for intestinal pseudo-obstruction, taking into account a patient's unique genetic makeup and lifestyle, which enhances symptom management and the effectiveness of therapy. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approvals in 2022. Therefore, the growing demand for personalized medicine is fueling the expansion of the intestinal pseudo-obstruction (IPO) treatment market.

In May 2023, Ironwood Pharmaceuticals, a pharmaceutical company headquartered in the United States, completed the acquisition of VectivBio Holding AG for an undisclosed sum. This strategic move is poised to bolster Ironwood's innovation capabilities and expand its portfolio, ultimately reshaping the benchmark for care in the field of gastrointestinal (GI) medicine. The acquisition will also propel advancements in the treatment of GI disorders, with VectivBio Holding AG, a clinical-stage biotechnology company based in Switzerland, specializing in the treatment of severe and rare gastrointestinal conditions, including Intestinal Pseudo-Obstruction (IPO).

Major companies operating in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.

North America was the largest region in the intestinal pseudo-obstruction treatment market in 2024. The regions covered in intestinal pseudo-obstruction (IPO) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intestinal pseudo-obstruction (IPO) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intestinal pseudo-obstruction (IPO) treatment market consists of revenues earned by providing entities by providing surgical interventions, decompression and nutrition support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestinal pseudo-obstruction (IPO) treatment market also includes sales of narcotics, laxatives and pro-kinetics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intestinal Pseudo-Obstruction Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intestinal pseudo-obstruction treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for intestinal pseudo-obstruction treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The intestinal pseudo-obstruction treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Intestinal Pseudo-Obstruction Treatment Market Characteristics

3. Intestinal Pseudo-Obstruction Treatment Market Trends And Strategies

4. Intestinal Pseudo-Obstruction Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Intestinal Pseudo-Obstruction Treatment Growth Analysis And Strategic Analysis Framework

6. Intestinal Pseudo-Obstruction Treatment Market Segmentation

7. Intestinal Pseudo-Obstruction Treatment Market Regional And Country Analysis

8. Asia-Pacific Intestinal Pseudo-Obstruction Treatment Market

9. China Intestinal Pseudo-Obstruction Treatment Market

10. India Intestinal Pseudo-Obstruction Treatment Market

11. Japan Intestinal Pseudo-Obstruction Treatment Market

12. Australia Intestinal Pseudo-Obstruction Treatment Market

13. Indonesia Intestinal Pseudo-Obstruction Treatment Market

14. South Korea Intestinal Pseudo-Obstruction Treatment Market

15. Western Europe Intestinal Pseudo-Obstruction Treatment Market

16. UK Intestinal Pseudo-Obstruction Treatment Market

17. Germany Intestinal Pseudo-Obstruction Treatment Market

18. France Intestinal Pseudo-Obstruction Treatment Market

19. Italy Intestinal Pseudo-Obstruction Treatment Market

20. Spain Intestinal Pseudo-Obstruction Treatment Market

21. Eastern Europe Intestinal Pseudo-Obstruction Treatment Market

22. Russia Intestinal Pseudo-Obstruction Treatment Market

23. North America Intestinal Pseudo-Obstruction Treatment Market

24. USA Intestinal Pseudo-Obstruction Treatment Market

25. Canada Intestinal Pseudo-Obstruction Treatment Market

26. South America Intestinal Pseudo-Obstruction Treatment Market

27. Brazil Intestinal Pseudo-Obstruction Treatment Market

28. Middle East Intestinal Pseudo-Obstruction Treatment Market

29. Africa Intestinal Pseudo-Obstruction Treatment Market

30. Intestinal Pseudo-Obstruction Treatment Market Competitive Landscape And Company Profiles

31. Intestinal Pseudo-Obstruction Treatment Market Other Major And Innovative Companies

32. Global Intestinal Pseudo-Obstruction Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intestinal Pseudo-Obstruction Treatment Market

34. Recent Developments In The Intestinal Pseudo-Obstruction Treatment Market

35. Intestinal Pseudo-Obstruction Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기